Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial

OBJECTIVE: To evaluate the efficacy, tolerability, and safety of once-daily 1200 mg and 2400 mg SPN-804 (Oxtellar XR™, Supernus Pharmaceuticals), an extended-release tablet formulation of oxcarbazepine (OXC), added to 1-3 concomitant antiepileptic drugs (AEDs) in adults with refractory partial-onset...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: French, JA, Baroldi, P, Brittain, ST, Johnson, JK
Médium: Artigo
Jazyk:Inglês
Vydáno: BlackWell Publishing Ltd 2014
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4033571/
https://ncbi.nlm.nih.gov/pubmed/24359313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ane.12207
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky